350 related articles for article (PubMed ID: 9932081)
1. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
2. [Clinical activity spectrum of irinotecan].
Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
[TBL] [Abstract][Full Text] [Related]
3. [Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials].
Couteau C; Yakendji K; Terret C; Goncalves E; Armand JP
Bull Cancer; 1996 Jan; 83(1):3-10. PubMed ID: 8672854
[TBL] [Abstract][Full Text] [Related]
4. CPT-11: clinical experience in phase I studies.
Armand JP
Semin Oncol; 1996 Feb; 23(1 Suppl 3):27-33. PubMed ID: 8633250
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan plus oxaliplatin: a promising combination for advanced colorectal cancer.
Wasserman E; Sutherland W; Cvitkovic E
Clin Colorectal Cancer; 2001 Nov; 1(3):149-53. PubMed ID: 12450427
[TBL] [Abstract][Full Text] [Related]
7. [Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Couteau C; Armand JP
Bull Cancer; 1998 Dec; Spec No():47-50. PubMed ID: 9932085
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
[TBL] [Abstract][Full Text] [Related]
9. CPT-11: the European clinical development.
Terret C; Couteau C; Armand JP
J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
[TBL] [Abstract][Full Text] [Related]
10. CPT-11. The European experience.
Armand JP; Terret C; Couteau C; Rixe O
Ann N Y Acad Sci; 1996 Dec; 803():282-91. PubMed ID: 8993522
[TBL] [Abstract][Full Text] [Related]
11. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer.
Rosati G; Cordio S
Tumori; 2006; 92(4):290-4. PubMed ID: 17036518
[TBL] [Abstract][Full Text] [Related]
12. [Irinotecan in combination for colon cancer].
Ducreux M; Gil-Delgado M; André T; Ychou M; de Gramond A; Khayat D
Bull Cancer; 1998 Dec; Spec No():43-6. PubMed ID: 9932084
[TBL] [Abstract][Full Text] [Related]
13. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
Van Cutsem E; Peeters M
Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of irinotecan in pediatric patients with malignant solid tumors.
Mugishima H; Matsunaga T; Yagi K; Asami K; Mimaya J; Suita S; Kishimoto T; Sawada T; Tsuchida Y; Kaneko M
J Pediatr Hematol Oncol; 2002 Feb; 24(2):94-100. PubMed ID: 11990713
[TBL] [Abstract][Full Text] [Related]
15. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Armand JP; Extra YM; Catimel G; Abigerges D; Marty M; Clavel M
Ann Oncol; 1996 Oct; 7(8):837-42. PubMed ID: 8922198
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Ribrag V; Koscielny S; Vantelon JM; Fermé C; Rideller K; Carde P; Bourhis JH; Munck JN
Leuk Lymphoma; 2003 Sep; 44(9):1529-33. PubMed ID: 14565655
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.
Rowinsky EK; Grochow LB; Ettinger DS; Sartorius SE; Lubejko BG; Chen TL; Rock MK; Donehower RC
Cancer Res; 1994 Jan; 54(2):427-36. PubMed ID: 8275479
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
19. Moving beyond fluorouracil for colorectal cancer.
Mayer RJ
N Engl J Med; 2000 Sep; 343(13):963-4. PubMed ID: 11006373
[No Abstract] [Full Text] [Related]
20. Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Berg D
Oncol Nurs Forum; 1998 Apr; 25(3):535-43. PubMed ID: 9568608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
